Prestige BioPharma and Alvogen have recently announced that they have entered into an exclusive partnership for the commercialization of Prestige BioPharma’s trastuzumab biosimilarin Central and Eastern Europe.
Prestige BioPharma and Alvogen have recently announced that they have entered into an exclusive partnership for the commercialization of Prestige BioPharma’s trastuzumab biosimilar in Central and Eastern Europe.
The proposed trastuzumab biosimilar will be seeking indications to treat human epidermal receptor 2 (HER2)-positive breast cancer, as well as HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. The potential biosimilar is currently in phase 3 clinical development and will be marketed as Hervelous.
“I am pleased to partner with Prestige BioPharma to further expand our biosimilar portfolio in the region… We have managed to secure a leading position in biosimilars in the region, with a robust portfolio of leading molecules for the treatment of oncology, rheumatoid arthritis, and anemia and the expected addition of [a] trastuzumab biosimilar will be a great addition to our biosimilar assets,” commented Hacho Hatchikian, executive vice president of Alvogen.
The agreement includes the exclusive rights for Alvogen to commercialize the proposed biosimilar in all of its Central and Eastern European markets. Although the exact terms of the arrangement have not been publicly disclosed, Prestige BioPharma will assume the responsibility of development and product registration with the European Medicines Agency (EMA), as well as the commercial supply of the biosimilar out of its manufacturing facilities in Osong, South Korea.
The companies plan to file with the EMA and the FDA for regulatory approval in 2019.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.